Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2024
Programm
Poster
Suche
DE
Zurück
Poster session
PoS 1
ePoster 02
Termin
Datum:
04.12.
Zeit:
17:00
–
18:00
Ort / Stream:
ePoster station 2
Programm
ePoster
P013
Establishing relationships between efficacy, tolerability and the serum concentration of candesartan when used as migraine prophylaxis
Hedda Skogum Riise (Trondheim, NO)
ePoster
P014
Vaporized Cannabis versus placebo for acute migraine – a randomized controlled trial
Nathaniel Schuster (San Diego, US)
ePoster
P015
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine – a retrospective, observational, multicenter, cohort study
Danilo Antonio Montisano (Milan, IT)
ePoster
P016
Role of SphenoCath procedure in the treatment of migraine – a retrospective study
Luisa Vinciguerra (Crema, IT)
ePoster
P017
Use of Rimegepant 75 mg for the acute treatment of migraine is associated with a reduction in monthly migraine days – a pooled analysis of 2 open-label trials
Yunjun Zou (Shanghai, CN)
ePoster
P018
A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): an open-label, prospective clinical study based on the stratification of responders to Erenumab
Daniele Martinelli (Pavia, IT)
ePoster
P019
Rimegepant effectiveness and tolerability as acute migraine treatment (GAINER) – a real-world multicentric study
Michele Corrado (Pavia, IT)
ePoster
P020
GLP-1 agonists for the treatment of chronic migraine: a pilot prospective observational cohort study
Simone Braca (Naples, IT)
ePoster
P021
Real-world experience of Lasmiditan for the acute treatment of migraine – a single clinic-based prospective study
Hoe Jong Jeong (Seoul, KR)
ePoster
P022
Conditioned pain modulation is associated with the prognosis in patients with migraine
Li-Ling Hope Pan (Taipei, TW)
ePoster
P023
Patients satisfaction to triptans and to available oral and injectable medications (OnabotulinumtoxinA/anti-CGRP MAbs) for migraine prophylaxis. Results of a web-based survey
Emmanouil V. Dermitzakis (Thessaloniki, GR)
ePoster
P024
Migraine patients treating with remote electrical neuromodulation (REN) shows significant and clinically meaningful benefits and utilization in a Coverage with evidence development (CED) study
Alit Stark-Inbar (Netanya, IL)
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz